Fennec Pharmaceuticals (FENC) Accounts Payables (2016 - 2025)
Fennec Pharmaceuticals (FENC) has disclosed Accounts Payables for 15 consecutive years, with $5.9 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Accounts Payables rose 51.69% year-over-year to $5.9 million, compared with a TTM value of $5.9 million through Sep 2025, up 51.69%, and an annual FY2024 reading of $3.2 million, down 14.21% over the prior year.
- Accounts Payables was $5.9 million for Q3 2025 at Fennec Pharmaceuticals, down from $5.9 million in the prior quarter.
- Across five years, Accounts Payables topped out at $5.9 million in Q2 2025 and bottomed at $677000.0 in Q2 2021.
- Average Accounts Payables over 5 years is $3.3 million, with a median of $3.0 million recorded in 2023.
- The sharpest move saw Accounts Payables tumbled 75.43% in 2021, then soared 157.46% in 2022.
- Year by year, Accounts Payables stood at $1.2 million in 2021, then soared by 107.11% to $2.4 million in 2022, then skyrocketed by 58.08% to $3.8 million in 2023, then dropped by 14.21% to $3.2 million in 2024, then surged by 80.99% to $5.9 million in 2025.
- Business Quant data shows Accounts Payables for FENC at $5.9 million in Q3 2025, $5.9 million in Q2 2025, and $5.3 million in Q1 2025.